



Nash, P., McInnes, I. B., Mease, P. J., Thom, H., Hunger, M., Karabis, A., Gandhi, K., Mpofu, S., & Jugl, S. M. (2018). Correction to: Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect Comparison. *Rheumatology and Therapy*.
<https://doi.org/10.1007/s40744-018-0117-3>

Publisher's PDF, also known as Version of record

License (if available):
CC BY

Link to published version (if available):
[10.1007/s40744-018-0117-3](https://doi.org/10.1007/s40744-018-0117-3)

[Link to publication record in Explore Bristol Research](#)
PDF-document

This is the final published version of the article (version of record). It first appeared online via Springer at <https://link.springer.com/article/10.1007%2Fs40744-018-0117-3> . Please refer to any applicable terms of use of the publisher.

University of Bristol - Explore Bristol Research

General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available:
<http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/>

CORRECTION

Correction to: Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect Comparison

Peter Nash · Iain B. McInnes · Philip J. Mease · Howard Thom ·
Matthias Hunger · Andreas Karabis · Kunal Gandhi · Shephard Mpofu ·
Steffen M. Jugl

© The Author(s) 2018

Correction to: Rheumatol Ther (2018) 5:99–122
<https://doi.org/10.1007/s40744-018-0106-6>

Under Methods section, heading Analyses: Pairwise Comparisons, one of the probability value was published incorrectly in a sentence. The correct sentence should read as follows:

In acknowledgment of the recent American Statistical Association statement on P values

and their preference to avoid such a threshold in clinical research [39, 40], our data were also analyzed using a more modern definition of the strength of evidence that P values can provide [41, 42] ($0.1 > P > 0.001$ as increasing evidence, $P \leq 0.001$ as strong evidence against the null hypothesis; Table S8 in the supplementary material).

The original article can be found online at <https://doi.org/10.1007/s40744-018-0106-6>.

P. Nash (✉)
University of Queensland, Brisbane, QLD, Australia
e-mail: drpnash@tpg.com.au

I. B. McInnes
University of Glasgow, Glasgow, UK

P. J. Mease
Swedish Medical Center and University of
Washington, Seattle, WA, USA

H. Thom
University of Bristol, Bristol, UK

M. Hunger
MAPI Group, Munich, Germany

A. Karabis
MAPI Group, Houten, The Netherlands

K. Gandhi
Novartis Pharmaceuticals Corporation, East
Hanover, NJ, USA

S. Mpofu · S. M. Jugl
Novartis Pharma AG, Basel, Switzerland

Open Access. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits any non-commercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.